If African-American researchers are ever to gain equal opportunities in science, even subtle cases of differential treatment must be stamped out.
The Scientist
Most Recent
Although fully organized patient-run trials are still few and far between, patients are taking a more active role in clinical research.
Agencies like the NSF and NIH are losing around 5 percent of their yearly budgets.
Patients are sidestepping clinical research and using themselves as guinea pigs to test new treatments for fatal diseases. Will they hurt themselves, or science?
The National Institutes of Health is weighing a peer-review system where grant proposals, even ones being resubmitted, would be treated as new.
The first human trial of a treatment using induced pluripotent stem cells has received conditional approval from an institutional review board in Japan.
Some of the 200 or so human embryonic stem cell lines approved for federal funding may have been derived from sperm or eggs of unconsenting donors.
Tuberculosis bacteria find shelter from drugs and the body’s defenses in bone marrow stem cells.
Using a SMART card containing your genetic information and medical history, you could one day soon be diagnosed and treated for all kinds of diseases at an ATM-style kiosk.
A new study disputes findings of a 2011 analysis suggesting that black researchers are funded less than their equally qualified white peers.
Follow The Scientist
Stay Connected with The Scientist
-
The Scientist Magazine
-
The Scientist Careers
-
Neuroscience Research Techniques
-
Genetic Research Techniques
-
Cell Culture Techniques
-
Microbiology and Immunology
-
Cancer Research and Technology
Current Issue
